Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.
- First Posted Date
- 2011-09-20
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT01437384
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)
- First Posted Date
- 2011-09-14
- Last Posted Date
- 2021-06-08
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01433991
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital / Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)
Phase 3
Terminated
- Conditions
- Idiopathic Thrombocytopenic Purpura
- Interventions
- First Posted Date
- 2011-09-14
- Last Posted Date
- 2018-02-06
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01433978
- Locations
- 🇺🇸
Prairie Lakes Health Care System, Watertown, South Dakota, United States
Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)
- Conditions
- Cancer
- First Posted Date
- 2011-09-13
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Eisai Inc.
- Registration Number
- NCT01432483
An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function
- First Posted Date
- 2011-08-17
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT01418677
Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs
Phase 3
Completed
- Conditions
- Lennox-Gastaut Syndrome
- Interventions
- Drug: Any other approved Antiepileptic Drug
- First Posted Date
- 2011-07-29
- Last Posted Date
- 2019-08-06
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT01405053
Demonstrate Bioequivalence Between 6 ? 2-mg Tablets of Perampanel and a Single 12-mg Tablet of Perampanel in Healthy Subjects
- First Posted Date
- 2011-07-19
- Last Posted Date
- 2012-05-04
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT01396590
Demonstrate Bioequivalence Between 3 x 2-mg Tablets of Perampanel and a Single 6-mg Tablet of Perampanel in Healthy Subjects
- First Posted Date
- 2011-07-19
- Last Posted Date
- 2012-05-04
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT01396577
A Efficacy and Safety Study of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures
Phase 3
Completed
- Conditions
- Seizure Disorder Generalized Tonic Clonic
- Interventions
- Drug: Placebo comparator
- First Posted Date
- 2011-07-13
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 163
- Registration Number
- NCT01393743
Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
- First Posted Date
- 2011-06-22
- Last Posted Date
- 2011-07-12
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT01378416
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
© Copyright 2025. All Rights Reserved by MedPath